Biopharming Research Unit, Department of Molecular & Cell Biology, University of Cape Town, Cape Town, South Africa.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 Mar;12(2):e1587. doi: 10.1002/wnan.1587. Epub 2019 Sep 5.
The use of plants for the production of virus-like nanoparticles (VNPs) dates back to separating natural empty capsids of plant viruses from whole virions nearly 70 years ago, through to the present use of transgenic plants or recombinant Agrobacterium tumefaciens and/or plant virus-derived vectors for the transient expression of engineered viral or other structural proteins in plants-a production system also known as molecular farming. Plant production of heterologous proteins has major advantages in terms of convenience-whole plants are generally used, and processes do not need to be sterile-and cost, as bulk biomass production is significantly cheaper than by any other method. Plant-made VNPs in current use for nanotechnology include whole virions and naturally occurring empty capsids of plant viruses, and particles made by reassembly of coat protein (CP) purified from virions or by recombinant expression. Engineered VNP-forming animal or human virus CPs expressed in plants include L1 protein from human papillomaviruses, human norovirus CP, hepatitis B surface and core antigens, influenza virus HA protein and HIV Gag polyprotein forming large enveloped particles by budding, orbi- and rotavirus particles that require assembly of four co-expressed proteins, and polio- and foot and mouth disease viruses which require proteolytic processing of a polyprotein precursor to form 4-component VNPs. Both plant and animal virus-derived plant-made VNPs can be used for surface and internal display of heterologous peptides or even whole proteins. A significant recent development has been the production of pseudovirions in plants, comprising plant or animal virus CPs and RNA or DNA pseudogenomes that can be used to deliver nucleic acid payloads into cultured cells or specific tissues or tumors in whole animals. This article is characterized under: Biology-Inspired Nanomaterials > Protein and Virus-Based Structures Therapeutic Approaches and Drug Discovery > Emerging Technologies Diagnostic Tools > in vivo Nanodiagnostics and Imaging.
植物生产病毒样纳米颗粒(VNPs)的历史可以追溯到近 70 年前,当时人们从完整的病毒粒子中分离出植物病毒的天然空衣壳,直到现在,人们使用转基因植物或重组根瘤农杆菌和/或植物病毒衍生的载体在植物中转基因表达工程病毒或其他结构蛋白,这种生产系统也被称为分子农业。与其他方法相比,植物生产异源蛋白具有明显的优势,因为整个植物通常被使用,并且过程不需要无菌,而且成本也更低,因为大规模生物质生产要便宜得多。目前用于纳米技术的植物生产 VNPs 包括完整的病毒粒子和植物病毒的天然空衣壳,以及通过重新组装从病毒粒子中纯化的外壳蛋白(CP)或通过重组表达制成的颗粒。在植物中表达的工程化 VNP 形成动物或人类病毒 CP 包括人乳头瘤病毒的 L1 蛋白、人类诺如病毒 CP、乙型肝炎表面和核心抗原、流感病毒 HA 蛋白和 HIV Gag 多蛋白,这些蛋白通过出芽形成大的包膜颗粒,或通过组装四个共表达的蛋白形成双顺反子和轮状病毒颗粒,以及脊髓灰质炎和口蹄疫病毒,这些病毒需要多蛋白前体的蛋白水解加工才能形成 4 个成分的 VNPs。植物和动物病毒衍生的植物制造的 VNPs 都可以用于异源肽甚至整个蛋白质的表面和内部显示。最近的一个重大进展是在植物中生产假病毒,包括植物或动物病毒 CP 和 RNA 或 DNA 假基因组,可用于将核酸有效载荷递送到培养细胞或整个动物的特定组织或肿瘤中。这篇文章的特点是:生物启发的纳米材料 > 基于蛋白质和病毒的结构治疗方法和药物发现 > 新兴技术诊断工具 > 体内纳米诊断和成像。